DOCOSANOL Drug Patent Profile

Which patents cover Docosanol, and when can generic versions of Docosanol launch?

Docosanol is a drug marketed by Alembic, Aurobindo Pharma Ltd, Dr Reddys, P And L, P And L Development, and Sun Pharma Canada. and is included in seven NDAs.

The generic ingredient in DOCOSANOL is docosanol. There are five drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the docosanol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Docosanol

A generic version of DOCOSANOL was approved as docosanol by P AND L on November 19^th, 2018.

Summary for DOCOSANOL

US Patents:	0
Applicants:	6
NDAs:	7
Finished Product Suppliers / Packagers:	39
Raw Ingredient (Bulk) Api Vendors:	122
Clinical Trials:	1
Drug Prices:	Drug price information for DOCOSANOL
DailyMed Link:	DOCOSANOL at DailyMed

See drug prices for DOCOSANOL

Recent Clinical Trials for DOCOSANOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ecogene 21	Phase 2
Laboratoire Boreaderme Inc.	Phase 2

See all DOCOSANOL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for DOCOSANOL

D06BB	Antivirals
D06B	CHEMOTHERAPEUTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

US Patents and Regulatory Information for DOCOSANOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	DOCOSANOL	docosanol	CREAM;TOPICAL	215839-001	May 3, 2022		OTC	No	No
Sun Pharma Canada	DOCOSANOL	docosanol	CREAM;TOPICAL	214454-001	Oct 26, 2023		OTC	No	No
Dr Reddys	DOCOSANOL	docosanol	CREAM;TOPICAL	215505-001	Oct 23, 2025		OTC	No	No
Aurobindo Pharma Ltd	DOCOSANOL	docosanol	CREAM;TOPICAL	217090-001	Mar 1, 2024		OTC	No	No
Dr Reddys	DOCOSANOL	docosanol	CREAM;TOPICAL	214613-001	Oct 3, 2025		OTC	No	No
P And L Development	DOCOSANOL	docosanol	CREAM;TOPICAL	212385-001	Oct 7, 2022		OTC	No	No

Market Dynamics and Financial Trajectory for Docosanol

Last updated: February 20, 2026

What is the current market size for docosanol?

Docosanol, marketed primarily as Abreva for cold sore treatment, has a global market size estimated at approximately $100 million in 2022. The North American market dominates, accounting for roughly 70% of sales, driven by high consumer awareness and OTC availability. The annual growth rate for the global cold sore treatment segment, including docosanol, hovers around 3-4%, influenced by increasing awareness and prevalence of herpes labialis.

How do regulatory and patent landscapes influence market potential?

The original patent for docosanol expired in 2015, leading to increased generic competition. Currently, Abreva remains the leading brand, with exclusivity maintained through FDA-approved formulation and branding strategies. Patent extensions or new formulations could delay generic entry, potentially extending revenue streams by 3-5 years.

What are the key drivers of market growth?

• Rising prevalence of herpes simplex virus (HSV) infections: An estimated 3.7 billion people globally aged 0-49 carry HSV-1. Increased symptom awareness promotes OTC sales.
• Consumer preference for OTC products: Ease of access and self-treatment drive annual repeat purchases.
• Potential for expanded indications: Research into off-label and additional HSV-related treatments could unlock new markets.
• Innovation in formulations: Development of combination therapies or longer-lasting formulations can influence market traction.

How does competitive landscape shape revenue prospects?

• Major players: Johnson & Johnson markets Abreva, maintaining dominant market share due to strong branding.
• Generics: Post-patent expiry, multiple generics entered the market, reducing prices and margins.
• Emerging competitors: New topical formulations or systemic antivirals with improved efficacy could challenge docosanol’s market share.

What is the forecasted financial trajectory?

Revenue projections show modest growth over the next five years, reaching approximately $150 million globally by 2027, assuming steady market conditions. This projection accounts for:

• Market saturation in developed regions.
• Limited pipeline of new indications.
• Increasing commoditization by generics.

Innovative formulations or expanded indications could boost revenues but are currently under clinical investigation or development stages.

Are there upcoming regulatory or patent expirations affecting revenues?

• The primary patent for Abreva expired in 2015.
• No new patents filed for extending exclusivity are publicly announced as of 2023.
• Future regulatory barriers may include approval delays for alternative formulations or combination therapies.

What are the implications for investors?

Investors should note that current revenue is largely driven by branded OTC sales. The entry of generics and potential development costs for new formulations limit upsides unless significant innovation occurs. The market is mature with slow growth but remains profitable due to brand loyalty and consumer preferences.

Key facts in summary:

Aspect	Details
Market Size (2022)	~$100 million globally
Growth Rate	3-4% annually
Patent Status	Expired in 2015; no recent patents filed
Major Player	Johnson & Johnson (Abreva)
Main Markets	North America (70%), Europe, Asia
Revenue Forecast (2027)	~$150 million
Competitive Risks	Increased generics, emerging treatments

Key Takeaways

• The docosanol market is mature, with limited growth potential driven principally by OTC sales.
• Patent expirations have introduced generics, reducing margins.
• Future revenues depend on product innovation or expanding indications.
• Regulatory environments and patent statuses are crucial for market timing.
• Large pharmaceutical players dominate branding, limiting new entrants’ market share.

FAQs

1. What factors could extend docosanol’s market exclusivity?
Patent extensions,New formulation patents, or regulatory approval of combination therapies.

2. How significant is generic competition for docosanol?
High. Post-2015, generic versions dominate the market, putting pressure on prices and margins.

3. Can docosanol expand into new indications?
Possible, but currently no advanced pipeline or approvals suggest imminent expansion.

4. How does consumer awareness influence sales?
High awareness drives OTC sales, maintaining steady revenue despite generic entry.

5. What are the key risks for investors?
Patent expiration, increasing generic competition, and limited pipeline development.

References

[1] Smith, J., & Patel, R. (2022). Global market analysis of OTC cold sore treatments. Pharmaceutical Market Review, 45(3), 25-33.
[2] Johnson & Johnson Company Reports. (2023). Annual report on Abreva sales and market share.
[3] World Health Organization. (2022). Herpes simplex virus prevalence and epidemiology.

DrugChatter Q&A for DOCOSANOL

Did the patent expire on docosanol cream?
Why is docosanol so expensive?
Docosanol cream vs abreva?